셀리드

IR

Cellid Co.,Ltd. leads development of anti-cancer immunotherapy.

Total of 10posts

Number	Title	Person with Duty to Submit	Receipt Date
10	Material Management Information related to Judgment of Investment(국책과제 선정(아데노바이러스 벡터를 기반으로 한 코로나19 예방백신의 임상 1/2a상 개발))	Cellid Co., Ltd.	2021-03-02
9	30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations)	Cellid Co., Ltd.	2021-02-24
8	Resolutions for Convocation of General Meeting of Shareholders	Cellid Co., Ltd.	2021-02-24
7	Material Management Information related to Judgment of Investment(코로나바이러스감염증-19 예방백신 임상 1/2a상 시험 계획 승인)	Cellid Co., Ltd.	2020-12-04
6	Additional Listing(주식매수선택권행사)	Cellid Co., Ltd.	2020-11-13
5	[Revised]Organization of Investor Relations Event	Cellid Co., Ltd.	2020-11-12
4	[Revised]Organization of Investor Relations Event	Cellid Co., Ltd.	2020-11-04
3	Material Management Information related to Judgment of Investment(코로나바이러스감염증-19(COVID-19) 예방백신(AdCLD-CoV19) 임상 제1/2a상 시험 계획(IND) 승인 신청)	Cellid Co., Ltd.	2020-10-07
2	Organization of Investor Relations Event	Cellid Co., Ltd.	2020-09-16
1	[Revised]Organization of Investor Relations Event	Cellid Co., Ltd.	2020-08-20